![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Adolor Corp. (MM) | NASDAQ:ADLR | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4.77 | 0 | 01:00:00 |
Adolor Corporation (Nasdaq:ADLR) today announced that it will hold a conference call at 9:00 a.m. ET on Wednesday, April 29, 2009 to discuss first quarter 2009 financial results.
To participate in the audio portion and have the opportunity to pose questions, dial (866) 394-4329 for domestic callers or (706) 902-1952 for international callers, and enter Conference ID # 96507883. Investors also can listen to the call live by logging on to the Company’s website at www.adolor.com and clicking on “Investor Insights,” then "Calendar of Events."
A replay of the call will be available beginning approximately two hours after the event. To listen to a replay of the conference call, dial (800) 642-1687 (domestic) or (706) 645-9291 (international) and enter Conference ID # 96507883 or listen via Adolor’s website. The replay will be available for one week.
About Adolor Corporation
Adolor Corporation is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products.
Adolor’s first approved product in the United States is ENTEREG® (alvimopan), which is indicated to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis. ENTEREG is available for short-term use in hospitals registered under the ENTEREG Access Support and Education (E.A.S.E.™) Program. In collaboration with GlaxoSmithKline (GSK), the Company launched ENTEREG in mid-2008.
The Company’s research and development pipeline includes: two novel delta opioid receptor agonists, currently in mid-stage clinical development in collaboration with Pfizer Inc. for chronic pain; a mu opioid receptor antagonist entering development for chronic opioid bowel dysfunction (OBD); and several opioid and non-opioid discovery programs.
For more information, visit www.adolor.com.
1 Year Adolor Corp. (MM) Chart |
1 Month Adolor Corp. (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions